Skip to main content
. 2018 Feb 2;35(2):153–161. doi: 10.1007/s40266-018-0523-9

Table 4.

Adverse outcomes for the total, control, and intervention cohorts

Adverse outcomes Total (N = 218) Control cohort (N = 125) Review cohort (N = 93) B, MD or OR 95% CI P value
Lower Upper
Duration of delirium in days, mean (range)a 12.52 (1–99) 15.47 (1–99) 8.56 (1–45)
 Interaction group × number of medications B = 0.08 0.02 0.15 0.01
 For patients taking 0–6 medications, mean 20.34 4.88 MD = 15.46 9.25 21.67 < 0.001
 For patients taking 7–11 medications, mean 13.6 9.86 MD = 3.74 − 0.35 7.83 0.07
 For patients taking 12 + medications, mean 10.57 8.76 MD = 1.81 − 4.15 7.78 0.55
Length of stay in days, median (range)a,b 16 (1–105) 17 (1–105) 15 (3–80) B = 0.88 0.71 1.09 0.22
Died in hospital, n (%) 24 (11%) 15 (12%) 9 (10%) OR = 0.74 0.305 1.814 0.51
Discharged back homec, n (%) 66 (37%) 39 (38%) 27 (36%) OR = 1.01 0.536 1.916 0.97

All models were corrected for age, sex, Charlson Comorbidity Index, and number of medications used by the patient

B unstandardised coefficient, CI confidence interval, MD mean difference from the generalised linear regression model, OR odds ratio

aFor the duration of delirium, an interaction effect between cohort and number of medications was found. To illustrate this interaction effect, the mean duration of delirium for patients taking 5, 10, 15 or 20 medications for both cohorts has been included in the table

bFor the length of stay, none of the covariates were significant; the table therefore displays the unadjusted model

cDischarged back home was only calculated for those patients living at home before hospital admission, and therefore has an N of 179 (N = 104 in the control condition, and N = 75 in the medication review condition)